XW0E33B Introduction of DB-OTO via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology...
ICD-10-PCS Procedure Codes
Code Added 2026-04-01
XW0E33B - Introduction of DB-OTO via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11The above description is abbreviated. This code description may also have Includes, Excludes, Notes, Guidelines, Examples and other information. Access to this feature is available in the following products:
The above description is abbreviated. This code description may also have Includes, Excludes, Notes, Guidelines, Examples and other information. |
XW0E33B Structure
| X | Section | New Technology |
| W | Body System | Anatomical Regions |
| 0 | Operation | Introduction |
| E | Body Part | Ear(s) |
| 3 | Approach | Percutaneous |
| 3 | Device / Substance / Technology | DB-OTO via Intracochlear Infusion |
| B | Qualifier | New Technology Group 11 |
XW0 Section Table
| Body Part | Approach | Device / Substance / Technology | Qualifier |
|---|---|---|---|
| 0 Skin | X External | 2 CPI-601 Enzyme Replacement Therapy | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | 1 Eladocagene exuparvovec 4 Stem Cells, Somatic | 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | 2 CPI-601 Enzyme Replacement Therapy L Paclitaxel-Coated Balloon Technology, Four or More Balloons | 9 New Technology Group 9 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | 6 Afamitresgene Autoleucel Immunotherapy | A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | 9 Odronextamab Antineoplastic V Xanomeline and Trospium Chloride | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | F Valoctocogene Roxaparvovec-rvox | 5 New Technology Group 5 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | G Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System H Paclitaxel-Coated Balloon Technology, One Balloon K Paclitaxel-Coated Balloon Technology, Three Balloons U COVID-19 Vaccine | 6 New Technology Group 6 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | S Iobenguane I-131 Antineoplastic | 6 New Technology Group 6 9 New Technology Group 9 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | T Melphalan Hydrochloride Antineoplastic | 6 New Technology Group 6 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | 3 Percutaneous | W AGN1 Bone Void Filler | 5 New Technology Group 5 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 1 Subcutaneous Tissue | X External | 2 CPI-601 Enzyme Replacement Therapy | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 2 Muscle | 0 Open | D Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension | 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 2 Muscle | 3 Percutaneous | S Iobenguane I-131 Antineoplastic T Melphalan Hydrochloride Antineoplastic U COVID-19 Vaccine | 6 New Technology Group 6 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 2 Muscle | 3 Percutaneous | V Xanomeline and Trospium Chloride W AGN1 Bone Void Filler X Peptide Enhanced Bone Void Filler Y Other New Technology Monoclonal Antibody | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | 0 Alpha1-proteinase Inhibitor | 8 New Technology Group 8 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | 1 Eladocagene exuparvovec | B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | 3 DB-OTO via Intracochlear Infusion 4 Stem Cells, Somatic D Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension | A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | 5 Ceftobiprole Medocaril Anti-infective 8 Mineral-based Topical Hemostatic Agent | 7 New Technology Group 7 8 New Technology Group 8 A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | 6 Afamitresgene Autoleucel Immunotherapy | 7 New Technology Group 7 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | 7 Tabelecleucel Immunotherapy | 2 New Technology Group 2 7 New Technology Group 7 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | 9 Odronextamab Antineoplastic | 6 New Technology Group 6 8 New Technology Group 8 A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | A Ciltacabtagene Autoleucel J Paclitaxel-Coated Balloon Technology, Two Balloons | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | B Orca-T Allogeneic T-cell Immunotherapy | 3 New Technology Group 3 7 New Technology Group 7 A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | C Zanidatamab Antineoplastic M Baricitinib N SER-109 | 7 New Technology Group 7 A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | E Remdesivir Anti-infective S Iobenguane I-131 Antineoplastic | 5 New Technology Group 5 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | F Valoctocogene Roxaparvovec-rvox | 3 New Technology Group 3 5 New Technology Group 5 A New Technology Group 10 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | G Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System H Paclitaxel-Coated Balloon Technology, One Balloon | 5 New Technology Group 5 6 New Technology Group 6 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | K Paclitaxel-Coated Balloon Technology, Three Balloons | 7 New Technology Group 7 9 New Technology Group 9 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | L Paclitaxel-Coated Balloon Technology, Four or More Balloons | 6 New Technology Group 6 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | P Antibiotic-eluting Bone Void Filler R Fostamatinib | 9 New Technology Group 9 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | Q Iloprost | 5 New Technology Group 5 9 New Technology Group 9 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 3 Peripheral Vein | 3 Percutaneous | W AGN1 Bone Void Filler | 5 New Technology Group 5 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | 0 Alpha1-proteinase Inhibitor | 8 New Technology Group 8 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | 1 Eladocagene exuparvovec | B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | 3 DB-OTO via Intracochlear Infusion 4 Stem Cells, Somatic | A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | 5 Ceftobiprole Medocaril Anti-infective 8 Mineral-based Topical Hemostatic Agent | 7 New Technology Group 7 8 New Technology Group 8 A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | 6 Afamitresgene Autoleucel Immunotherapy | 7 New Technology Group 7 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | 7 Tabelecleucel Immunotherapy | 2 New Technology Group 2 7 New Technology Group 7 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | 9 Odronextamab Antineoplastic | 6 New Technology Group 6 8 New Technology Group 8 A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | A Ciltacabtagene Autoleucel J Paclitaxel-Coated Balloon Technology, Two Balloons | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | B Orca-T Allogeneic T-cell Immunotherapy | 3 New Technology Group 3 7 New Technology Group 7 A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | C Zanidatamab Antineoplastic M Baricitinib N SER-109 | 7 New Technology Group 7 A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | E Remdesivir Anti-infective S Iobenguane I-131 Antineoplastic | 5 New Technology Group 5 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | F Valoctocogene Roxaparvovec-rvox | 3 New Technology Group 3 5 New Technology Group 5 A New Technology Group 10 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | G Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System H Paclitaxel-Coated Balloon Technology, One Balloon | 5 New Technology Group 5 6 New Technology Group 6 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | K Paclitaxel-Coated Balloon Technology, Three Balloons | 7 New Technology Group 7 9 New Technology Group 9 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | L Paclitaxel-Coated Balloon Technology, Four or More Balloons | 6 New Technology Group 6 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | P Antibiotic-eluting Bone Void Filler R Fostamatinib | 9 New Technology Group 9 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | Q Iloprost | 5 New Technology Group 5 9 New Technology Group 9 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 4 Central Vein | 3 Percutaneous | W AGN1 Bone Void Filler | 5 New Technology Group 5 B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 5 Peripheral Artery | 3 Percutaneous | 4 Stem Cells, Somatic | B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 5 Peripheral Artery | 3 Percutaneous | T Melphalan Hydrochloride Antineoplastic | 9 New Technology Group 9 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| 6 Cerebral Ventricle | 3 Percutaneous | 2 CPI-601 Enzyme Replacement Therapy | B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| D Mouth and Pharynx | X External | 3 DB-OTO via Intracochlear Infusion K Paclitaxel-Coated Balloon Technology, Three Balloons | 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| D Mouth and Pharynx | X External | 8 Mineral-based Topical Hemostatic Agent | 2 New Technology Group 2 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| D Mouth and Pharynx | X External | F Valoctocogene Roxaparvovec-rvox | 5 New Technology Group 5 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| D Mouth and Pharynx | X External | J Paclitaxel-Coated Balloon Technology, Two Balloons N SER-109 | 9 New Technology Group 9 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| D Mouth and Pharynx | X External | M Baricitinib | 6 New Technology Group 6 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| D Mouth and Pharynx | X External | R Fostamatinib | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| D Mouth and Pharynx | X External | V Xanomeline and Trospium Chloride | B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| E Ear(s) | 3 Percutaneous | 3 DB-OTO via Intracochlear Infusion | B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| G Upper GI | 7 Via Natural or Artificial Opening | 3 DB-OTO via Intracochlear Infusion K Paclitaxel-Coated Balloon Technology, Three Balloons | 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| G Upper GI | 7 Via Natural or Artificial Opening | M Baricitinib | 6 New Technology Group 6 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| G Upper GI | 7 Via Natural or Artificial Opening | R Fostamatinib | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| G Upper GI | 8 Via Natural or Artificial Opening Endoscopic | 8 Mineral-based Topical Hemostatic Agent | 6 New Technology Group 6 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| H Lower GI | 7 Via Natural or Artificial Opening | 3 DB-OTO via Intracochlear Infusion K Paclitaxel-Coated Balloon Technology, Three Balloons X Peptide Enhanced Bone Void Filler | 8 New Technology Group 8 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| H Lower GI | 7 Via Natural or Artificial Opening | M Baricitinib | 6 New Technology Group 6 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| H Lower GI | 7 Via Natural or Artificial Opening | R Fostamatinib | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| H Lower GI | 8 Via Natural or Artificial Opening Endoscopic | 8 Mineral-based Topical Hemostatic Agent | 6 New Technology Group 6 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| J Coronary Artery, One Artery K Coronary Artery, Two Arteries L Coronary Artery, Three Arteries M Coronary Artery, Four or More Arteries | 3 Percutaneous | H Paclitaxel-Coated Balloon Technology, One Balloon J Paclitaxel-Coated Balloon Technology, Two Balloons K Paclitaxel-Coated Balloon Technology, Three Balloons L Paclitaxel-Coated Balloon Technology, Four or More Balloons | A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| Q Cranial Cavity and Brain | 3 Percutaneous | 1 Eladocagene exuparvovec | 6 New Technology Group 6 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| U Joints | 0 Open | G Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System | A New Technology Group 10 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| U Joints | 0 Open | X Peptide Enhanced Bone Void Filler | B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| U Joints | 3 Percutaneous 4 Percutaneous Endoscopic | X Peptide Enhanced Bone Void Filler | B New Technology Group 11 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| V Bones | 0 Open | P Antibiotic-eluting Bone Void Filler | 7 New Technology Group 7 |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
| V Bones | 3 Percutaneous | W AGN1 Bone Void Filler | A New Technology Group 10 |
Additional Code Information includes:
Access to this feature is available in the following products:
|
ICD-10-PCS Index Entries (Reverse Index Lookup) 
reverse_index/reverse_index_content.php?set=ICD10PCS&c=XW0E33B
View historical information about the code including when it was added, changed, deleted, etc. Access to this feature is available in the following products:
|
Subscribers may add their own notes as well as "Admin Notes" visible to all subscribers in their account. Access to this feature is available in the following products:
Subscribers may add their own notes as well as "Admin Notes" visible to all subscribers in their account. |
Subscribers will see related documentation, coding and billing tips. Access to this feature is available in the following products:
|
View the general equivalency mappings (GEMs) between the ICD-9 and ICD-10 code sets. Access to this feature is available in the following products:
|
Cross-A-Code™ (ICD-9/10, CPT, Modifiers, NCCI, NDC, ASA CROSSWALK®)
crosswalks/crosswalk_content.php?set=ICD10PCS&c=XW0E33B
View relationships (or crosswalks) between code sets. Access to this feature is available in the following products:
|
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com
